EMBC Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.42%, SMA50 -2.85%, SMA200 -0.69%). The stock’s 14-day RSI is 48.07 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.52% below its high and over 33.59% above its low. Average 10-day trading volume of 425.06 thousand shares is below the 3-month average of 563.97 thousand, indicating normal recent market interest.

Embecta Corp. (NASDAQ:EMBC) closed at $12.33 USD, gaining $0.04 (0.33%) from the previous close of $12.29. The stock is currently mid-range between its 52-week high and low $9.20 and $19.67. With a market capitalization of about $730.08 million, Embecta Corp. is classified as a small-cap and shows market-like volatility (beta ~1.07). Key stats such as the average daily volume over the past year has been around 579.15 thousand shares, volume is running light vs its 52-week average. Headquartered in Parsippany, NJ, Embecta Corp. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Devdatt Kurdikar, the company employs approximately 2,000 people and listed since March 22, 2022. Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes.

Embecta Corp. has 58.49 million shares outstanding. The public float is 57.24 million shares, elevated short interest at 7.46% of float. This equals 3.11 million shares. The short ratio is 5.37 days. Institutional investors hold 102.03% of the float. Insiders own 0.47%. Kurdikar Devdatt holds 244.79 thousand shares, Melcher David F has 86.68 thousand shares and Elguicze Jacob has 66.03 thousand shares.

Wall Street analysts project EPS growth of 0.06% annually over the next five years. The latest quarter delivered EPS of $nan. The next quarter is forecast at $0.67. Next year's EPS is expected at $10.99. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $12.00. The high target offers 103.42% upside. The low target suggests -2.36% downside. The mean target is $16.25. This offers 32.22% upside.

Embecta Corp. last paid a dividend of 0.6 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $26.48. This means the shares are trading below this model’s fair value.

Embecta Corp. trades at a P/E ratio of 7.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.67 and a price-to-book ratio of -1.1 indicating negative book value, which may reflect financial stress. The P/FCF stands at 3.97, also above market averages.

Our AI price prediction model suggests that Embecta Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.74%, with price expected at $12.75 by February 03, 2026, within a range of $12.42 to $13.13 3-Month Outlook: Projected fall of -21.72%, reaching $9.62 by April 16, 2026, with a range of $8.63 to $10.29. 1-Year Outlook: Projected gain of 86.66%, with price at $22.94 by January 15, 2027, within a range of $0.54 to $38.55.

Embecta Corp. (NASDAQ:EMBC) shares are flat 3.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Embecta Corp. trading at a premium to the broader market with a P/E of 7.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.56, suggesting 75.43% upside. Our AI forecast model points to short-term strength (3.74% over two weeks), a medium-term fall (-21.72% over three months), and a longer-term gain (86.66% over one year), with expected trading ranges indicating moderate volatility.